HOUSTON, May 15, 2024 — CrossBridge Bio, Inc. (CrossBridge), a pioneering pre-clinical stage biotechnology company dedicated to advancing antibody-drug conjugate (ADC) therapeutics for unmet needs through stable dual linker payload technology that aims to significantly improve safety as well as potency/durability while addressing tumor resistance and heterogeneity, proudly announces the receipt of a substantial competitive non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant marks a significant milestone in CrossBridge’s mission to propel its innovative dual-payload ADC platform and potential best-in-class TROP2 program, CBB-120, to IND-enabling studies. 

CrossBridge’s cutting-edge ADC platform is at the forefront of cancer treatment innovation, utilizing site-specific antibody-branched linker conjugation, a stable tripeptide linker, and the ability to conjugate dual payloads via click chemistry. With the non-dilutive grant, CrossBridge is ready to accelerate the pre-clinical development of CBB-120 as a potential differentiated therapeutic for triple-negative breast cancers, hormone-positive Her2-negative breast cancers, and various other TROP2+ cancers with unmet needs, where our dual payloads will be most effective. 

“The data we will generate with this grant will support de-risking our next-generation ADC platform and provide another potential option for cancer patients. We are thankful for the review committee and CPRIT for funding CBB-120.” CEO and Co-Founder, Michael Torres, Ph.D. 

We sincerely thank the Cancer Prevention and Research Institute of Texas (CPRIT) for their support. The $2.6 million seed award highlights CrossBridge’s unwavering commitment to advancing ADC therapeutics and providing transformative treatments to patients with challenging cancers. This funding will boost our pre-clinical efforts and strengthen our position as a trailblazer in ADC innovation. 

About CrossBridge Bio, Inc. 

CrossBridge Bio is a Houston-based pre-clinical stage biotech company that develops advanced antibody-drug conjugates (ADCs) targeting various cancers. We are leveraging technology from the labs of Kyoji Tsuchikama and Zhiqiang An from UTHealth Houston, including a proprietary linker that offers greater stability and the ability to attach multiple payloads. Our core mission is to address unmet needs in cancer treatment by advancing the next generation of stable ADC therapeutics that carry dual payloads. This approach aims to improve therapeutic indices and tackle tumor heterogeneity and resistance. Learn more at www.crossbridgebio.com.  

About CPRIT 

Created by the Texas Legislature and approved by a statewide vote in 2007, the Cancer Prevention and Research Institute of Texas (CPRIT) leads the Lone Star State’s fight against cancer. In 2019, Texas voters again voted overwhelmingly to support CPRIT with an additional $3 billion, for a total $6 billion investment in cancer research and prevention. To date, the agency has awarded more than $3 billion in grants to Texas research institutions and organizations through its academic research, prevention, and product development research programs. CPRIT has also recruited 302 distinguished researchers to Texas, supported the establishment, expansion, or relocation of 62 companies to Texas, and supported 9.3 million prevention services reaching all 254 counties in Texas. Learn more about CPRIT at www.cprit.texas.gov